NCT03954873 (GLANCE) is a NA clinical trial of Glucagon-like peptide 2 in Glucose Metabolism Disorders, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT03954873?

NCT03954873 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT03954873?

Interventions in NCT03954873: Glucagon-like peptide 2, Saline, Glucose, Insulin.

What condition does NCT03954873 study?

NCT03954873 studies Glucose Metabolism Disorders, Endocrine or Metabolic Disease.

Is NCT03954873 still recruiting?

NCT03954873 is currently completed. Last updated 4 November 2020.

Last reviewed 2020-11-04 · How we verify

NCT03954873: GLANCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?

Completed NA Last updated 4 November 2020

What this trial tests

NA trial testing Glucagon-like peptide 2 in Glucose Metabolism Disorders in 10 participants. Completed in 1 June 2020.

Timeline

31 January 2019

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	10
Start date	31 January 2019
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	1 location across Denmark

Drugs / interventions tested

Glucagon-like peptide 2
Saline
Glucose — full drug profile →
Insulin (insulin) — full drug profile →

Conditions studied

Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →
Endocrine or Metabolic Disease — all drugs for Endocrine or Metabolic Disease →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 18 to 40, male only, with Glucose Metabolism Disorders or Endocrine or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Infusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes.
Kim A, Knudsen JG, Madara JC, Benrick A, et al · · 2021 · cited 31× · PMID 34787082 · DOI 10.7554/elife.72919
Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men.
Sørum NE, Magnussen T, Hansen NL, Nielsen CK, et al · · 2026 · PMID 41541287 · DOI 10.1210/jendso/bvaf215

Verify or expand the search:

Other recruiting trials for Glucose Metabolism Disorders

Currently open trials in the same condition.

NCT06763562 — Food Orders on Blood Glucose and Fuel Use At Rest · NA · recruiting
NCT06674980 — Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DF · NA · recruiting
NCT06051318 — Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects · NA · recruiting
NCT06358716 — Glycaemic Index Determination in Oral Nutrition Supplements · NA · recruiting
NCT06878781 — Postprandial Metabolome and Metabolic Flexibility · NA · recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03954873 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing